OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 20:40:05 14/06/2024 BST | ||
| 12.67 EUR | +1.85% |
|
| Current month | -31.22% | ||
| 1 month | -45.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 12.67 | +1.85% |
| 13/06/24 | 12.44 | -8.66% |
| 12/06/24 | 13.62 | -0.44% |
| 11/06/24 | 13.68 | -2.84% |
| 10/06/24 | 14.08 | -6.94% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 08:40 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW145V |
| ISIN | DE000SW145V2 |
| Date issued | 10/08/2023 |
| Strike | 1,015 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 44.9 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 47.16 € |
|---|---|
| Lowest since issue | 11.44 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Certificates
- Certificat